comparemela.com

Latest Breaking News On - Silvan tuerkcan - Page 1 : comparemela.com

StockWatch: MacroGenics Shares Crater after Trial Deaths

StockWatch: MacroGenics Shares Crater after Trial Deaths
genengnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from genengnews.com Daily Mail and Mail on Sunday newspapers.

Silvan tuerkcanBenzamide azaindoleEtzer daroutJonathan changSeana mccarthyDphil cytomMitchell kapoorRobert driscollPeter lawson barclaysStephen willey stifelScott koenigHc wainwright coMerck coMacrogenics presidentGetty imagesLeerink partners

MacroGenics (MGNX) Q1 2024 Earnings Call Transcript

MacroGenics (MGNX) Q1 2024 Earnings Call Transcript
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.

United statesJon miller evercoreEtzer daroutPeter lawsonKelsey goodwinAshiq mubarackMayank mamtanib rileyKaveri pohlmanSilvan tuerkcanJon millerJonathan chang leerinkJim karrelsStephen willeyYigal nochomovitzScott koenigJonathan chang

Exelixis (EXEL) Q1 2024 Earnings Call Transcript

EXEL earnings call for the period ending March 31, 2024.

Joe catanzaro piper sandlerWilliam blairAndy hsiehGregory renzaAmy petersonJennifer chanLukas shumwayEtzer daroutLaura dillardDavid lebowitzChris shibutani goldman sachsSilvan tuerkcanChris sennerPeter lawsonChris shibutaniMorgan stanley

Loads of analysts just hiked price targets for these 6 stocks — giving one 82% upside

CNBC Pro screened for global stocks that have received price target upgrades from five or more analysts and have an upside of over 25%.

South koreaSouth koreanJared issacmanPeter heckmannSilvan tuerkcanDan dolevFormula one groupHyundai motorMacrogenics investmentLeerlink partnersNew york listedMizuho securitiesShift4 payments incSemtech corpLiberty media corpMacrogenics inc

Buy Rating Affirmed for Crispr Therapeutics with Increased Price Target Following EU Approval and Capital Boost

Analyst Silvan Tuerkcan of JMP Securities maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report), with a price target .

Silvan tuerkcanEuropean unionAnalyst silvan tuerkcanCrispr therapeuticsResearch reportSickle cell diseaseTransfusion dependent thalassemiaTruist financialTipranks premium

vimarsana © 2020. All Rights Reserved.